U.S. Vascular Patches Market Size, Share & Forecast 2026–2032

ID: MR-11700 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: U.S. Vascular Patches Market
  • ✓Market Size 2024: USD 412 million
  • ✓Market Size 2032: USD 668 million
  • ✓CAGR: 6.2%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Procurement Sets Material Share: Medicare's fixed MS-DRG payments for carotid endarterectomy push hospital value analysis committees toward bovine pericardium and polyester patches. Gore's ePTFE franchise survives only through group purchasing contracts with Vizient and Premier. Price, not surgeon preference, now sets patch share.
FINDING 02
Biologics Will Not Displace Synthetics: Consensus expects biologic patches to displace synthetics. Synthetics will hold share through 2032. FDA 510(k) predicate pathways let Terumo and Getinge extend synthetic lines, while bovine pericardium supply tied to Artivion's tissue processing keeps biologics capacity-constrained.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Dual-Source Pricing Now: Hospital value analysis teams should lock multi-year patch pricing with two qualified suppliers before the FY2027 IPPS rate year begins on October 1, 2026. DRG reweighting will tighten device margins, and dual-sourcing protects procedure volumes against single-supplier price increases.

Vascular Patches in the United States: Market Overview

The U.S. vascular patches market was valued at USD 412 million in 2024 and is forecast to reach USD 668 million by 2032. Patches are sterile surgical inserts used to close arteriotomies and reconstruct carotid, peripheral and cardiac vessels, sold in PTFE, polyester, bovine pericardial and collagen-based formats. Private manufacturers dominate product design and sales, but CMS payment rules set the economics for every procedure in which a patch is used.

Government is the dominant force on the demand side. Medicare and Medicaid finance most vascular surgery for older patients, and the Department of Veterans Affairs procures through Federal Supply Schedule contracts and its Medical-Surgical Prime Vendor program, which fix national pricing. Private sector leadership is strongest in research and product line extensions, where Gore, Terumo and Getinge file 510(k) submissions at pace. Payers define price and manufacturers define innovation.

Policy-Driven Growth in U.S. Vascular Patches

Medicare's Inpatient Prospective Payment System, governed by 42 CFR Part 412, pays hospitals a fixed Medicare Severity Diagnosis-Related Group (MS-DRG) rate for carotid endarterectomy and peripheral arterial bypass. Because the rate covers all consumables, hospitals absorb patch cost but still perform these procedures at volume. Patch consumption therefore tracks the aging Medicare population with symptomatic carotid and peripheral artery disease.

Two newer mechanisms accelerate premium adoption. New Technology Add-On Payments under 42 CFR 412.87 reimburse up to 65 percent of device costs above the DRG rate for eligible technologies, letting hospitals adopt biologic or bioresorbable patches before long-term outcomes data arrive. CMS's Transitional Coverage for Emerging Technologies pathway, finalized in 2024, extends coverage for breakthrough devices and shortens the lag between FDA clearance and reimbursed use.

Regulatory Barriers and Compliance Costs

FDA premarket clearance is the first barrier. Most vascular patches are cleared through the 510(k) pathway under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, which carries a standard review goal of 90 FDA days and a FY2025 user fee of roughly USD 26,000. Manufacturers introducing novel biologic sources or bioresorbable polymers face the premarket approval pathway instead, where study costs often exceed USD 1 million and timelines run multiple years.

Quality system compliance adds a second layer. The FDA's Quality Management System Regulation, which amends 21 CFR Part 820 and takes effect February 2, 2026, incorporates ISO 13485:2016 requirements and forces suppliers to rebuild design-control and supplier-audit records. Unique Device Identification under 21 CFR Part 801 requires GUDID labelling, and analyst estimates put implementation costs for smaller suppliers between USD 100,000 and USD 300,000.

Policy-Created Opportunities in the United States

The Department of Veterans Affairs is the largest single federal buyer of vascular supplies. Its Medical-Surgical Prime Vendor program and Federal Supply Schedule create standing demand for standardized patches across roughly 170 VA medical centers. Suppliers that secure General Services Administration schedule listings gain access to every VA facility without separate tenders.

TCET and NTAP together reward first-to-market biologic patches. Manufacturers holding an FDA breakthrough device designation can route products into TCET, which opens reimbursement before a full national coverage determination. Tissue engineering programmes supported by the National Heart, Lung, and Blood Institute, including translational work at the Wake Forest Institute for Regenerative Medicine, offer development partnerships for suppliers building next-generation materials.

Market at a Glance

MetricValue
Market Size 2024USD 412 million
Market Size 2032USD 668 million
Growth Rate (CAGR)6.2%
Most Critical Decision FactorCMS DRG reimbursement and NTAP eligibility for new materials
Largest RegionSouth (Census region)
Competitive StructureConsolidated; top five suppliers hold the majority share

Leading Market Participants

  • W. L. Gore & Associates
  • Getinge
  • Terumo Corporation
  • LeMaitre Vascular
  • Artegraft
  • Becton, Dickinson and Company
  • Medtronic
  • Cook Medical
  • Ethicon
  • Artivion

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, administered by the FDA's Center for Devices and Radiological Health. Medical Device User Fee Amendments of 2022 (MDUFA V), enacted under the Consolidated Appropriations Act, 2023, set review performance goals through FY2027. Key compliance requirements include establishment registration, 510(k) or premarket approval submissions, QMSR compliance from February 2, 2026, UDI labelling, and Medical Device Reporting under 21 CFR Part 803. MDUFA VI negotiations must conclude before the September 2027 reauthorization deadline.

Federal anti-fraud rules add compliance overhead. The Anti-Kickback Statute at 42 U.S.C. 1320a-7b(b) and the Physician Payments Sunshine Act, codified at 42 U.S.C. 1320a-7h, require manufacturers to report surgeon payments through CMS Open Payments. Compared with the European Union, where Regulation (EU) 2017/745 imposes notified-body review on each patch, the U.S. 510(k) route is faster. Canada's Medical Devices Regulations (SOR/98-282) and Japan's PMDA framework sit between the two systems in review speed.

Long-Term Policy Outlook for U.S. Vascular Patches

By 2032, the QMSR will be fully embedded across the supplier base, and MDUFA VI will set review goals for novel biologic patches. CMS will expand transitional coverage pathways for breakthrough devices, which accelerates the commercial path for bioresorbable and tissue-based materials. Manufacturers without QMSR-ready quality systems will exit or consolidate before that horizon.

Cost containment will reshape the market. CMS's annual expansions of the Ambulatory Surgical Center covered procedures list will move more carotid and peripheral closure cases into ambulatory surgery centers, where fixed rates under the ASC payment system apply. Patch suppliers will respond with lower-price, kit-based products, and hospital systems will shift volume toward standardized synthetic patches.

Frequently Asked Questions

Most patches are cleared through the 510(k) premarket notification pathway under the Federal Food, Drug, and Cosmetic Act. Novel biologic or bioresorbable designs typically require premarket approval.
The FDA's Quality Management System Regulation takes effect on February 2, 2026, aligning 21 CFR Part 820 with ISO 13485:2016. Manufacturers must update design-control and supplier documentation before that date.
Generally no, because patch costs fall within MS-DRG payments for inpatient procedures. New Technology Add-On Payments can supplement reimbursement for eligible new technologies for a limited period.
VA buys through Federal Supply Schedule contracts administered by the General Services Administration and through the Medical-Surgical Prime Vendor program. Suppliers need schedule listing to access VA medical centers without separate tenders.
Manufacturers must report payments and transfers of value to physicians under the Physician Payments Sunshine Act through CMS Open Payments. Non-compliance carries civil monetary penalties.

Market Segmentation

By Material Type
  • PTFE
  • Polyester (Dacron)
  • Bovine Pericardium
  • Collagen-Based
  • Bioresorbable Polymer
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • VA Medical Centers
  • Specialty Vascular Clinics
By Application
  • Carotid Endarterectomy
  • Peripheral Vascular Repair
  • Cardiac Vascular Reconstruction
  • Aortic Repair

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Vascular Patches - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Material Type Insights
4.1 PTFE
4.2 Polyester (Dacron)
4.3 Bovine Pericardium
4.4 Collagen-Based
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Ambulatory Surgical Centers
5.3 VA Medical Centers
5.4 Specialty Vascular Clinics
5.5 Others
Chapter 06 Application Insights
6.1 Carotid Endarterectomy
6.2 Peripheral Vascular Repair
6.3 Cardiac Vascular Reconstruction
6.4 Aortic Repair
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.1.1 W. L. Gore & Associates
7.1.2 Getinge
7.1.3 Terumo Corporation
7.1.4 LeMaitre Vascular
7.1.5 Artegraft
7.1.6 Becton, Dickinson and Company
7.1.7 Medtronic
7.1.8 Cook Medical
7.1.9 Ethicon
7.1.10 Artivion
7.2 Regulatory Environment
7.3 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.